Posted by Michael Wonder on 23 May 2023
FDA approves new buprenorphine treatment option for opioid use disorder
23 May 2023 - Today, the US FDA approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder.
Brixadi is available in two formulations, a weekly injection that can be used in patients who have started treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, and a monthly version for patients already being treated with buprenorphine.
